SGPL1 and rheumatoid arthritis: Examples include early studies in RA with a sphingosine-1-phosphate lyase inhibitor to modulate lymphocyte redistribution, or with the chemokine receptor-1 antagonist involved in osteoclast maturation, mobility and activation [54].